Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0NZUZJ)
| ADC Name |
Varsetatug masetecan
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
varsetatug masetecan; EpCAM-PDC; CX-2051; Varseta-M
Click to Show/Hide
|
|||||
| Organization |
CytomX Therapeutics (Originator);ImmunoGen (Top20 MNC)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Varsetatug
|
Antibody Info | ||||
| Antigen Name |
Epithelial cell adhesion molecule (EPCAM)
|
Antigen Info | ||||
| Payload Name |
CAMP59
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
L-ala-ala-ala (TAL)
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
masetecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC